Roche pays $700M upfront in $2.3B blood-cancer drug deal with Nurix
Swiss drugmaker Roche said Monday it entered into an exclusive licensing and collaboration agreement with Nurix Therapeutics to develop a blood-cancer treatment, in a deal valued at up to $2.3 billion.
3 MIN READ